27/07/2009 (Agence Europe) - In a press release of 23 July, the European Medicines Agency announced that it had requested Sanofi-Aventis to continue research into a possible link between the use of certain insulin substitutes (lantus and optisulin) and an increased risk in cancer, particularly breast cancer. (O.J./trans/rh)